European Patent Office

T 0032/17 (Bispecific antibody/ DIASOURCE) vom 02.07.2020

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2020:T003217.20200702
Datum der Entscheidung
2. Juli 2020
Aktenzeichen
T 0032/17
Antrag auf Überprüfung von
-
Anmeldenummer
10189130.7
Verfahrenssprache
Englisch
Verteilung
An die Kammervorsitzenden verteilt (C)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
Process for the production of a hybridoma and antibody obtained therefrom, able to recognize more than one vitamin D metabolite.
Name des Antragstellers
Diasource Immunoassays S.A.
Name des Einsprechenden
Nederlandsch Octrooibureau N.V.
Immundiagnostik AG
Siemens Healthcare Diagnostics Inc.
Euroimmun Medizinische Labordiagnostika AG
Adams, Harvey Vaughan John
Kammer
3.3.04
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 112(1)(a)European Patent Convention Art 54European Patent Convention Art 83European Patent Convention R 31Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)
Schlagwörter
Main request - novelty (no)
Late-filed auxiliary requests 1 and 2
Late-filed auxiliary requests - admitted (no)
Late-filed facts - admitted (no)
Referral to the Enlarged Board of Appeal - (no)
Auxiliary request 3 - requirements of the EPC met (yes)
Orientierungssatz
The deposit of a hybridoma under Rule 31 EPC for compliance with the disclosure requirement of Article 83 EPC does not in itself convey any technical information about the molecular structure of the monoclonal antibody produced by said hybridoma, such as its amino acid sequence (see points 5 to 17 of the Reasons).

Order

For these reasons it is decided that:

1. The request for referral to the Enlarged Board of Appeal is refused.

2. The decision under appeal is set aside.

3. The case is remitted to the opposition division with the order to maintain the patent on the basis of the claim of auxiliary request 3, filed during the oral proceedings of 2 July 2020, and a description to be adapted thereto.